Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Sophie Deng (ucla)

Description

Summary

This phase I study will collect preliminary information on the activity and safety of cLSC. We will investigate the ability to manufacture and transplant cLSC onto the cornea successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular surface (efficacy) without serious adverse events (safety).

Official Title

Safety and Feasibility of Cultivated Autologous Limbal Stem Cells (cLSC) for Limbal Stem Cell Deficiency

Details

20 patients with severe to total Limbal Stem Cell Deficiency (LSCD) in one eye attributable to injury or ocular surgery. The first 5 eyes will receive the cLSCs to determine the feasibility and safety. Then the subsequent 15 eyes will be randomized into cLSC group and a scleral lens treatment (SCL) control group in a 2:1 ratio in blocks of 3 or 6 using a random number generator.

Keywords

Limbal Stem-cell Deficiency, Limbal Stem Cell Deficiency, cLSC, Scleral contact lens (SCL), Cultivated Limbal Stem-Cells (cLSC), Scleral Contact Lens Device (SCL)

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Male or female ≥18 years of age.
  2. Best corrected visual acuity in the affected eye of 20/200 or less.
  3. Documentation of a LSCD diagnosis and the central cornea is affected.
  4. Absence of lagophthalmos and eyelid abnormality
  5. Adequate forniceal depth is ≥ 5 mm.
  6. LSCD fails to resolve by surgical treatments of the ocular surface during the previous 6 months of screening visit.
  7. If the etiology of LSCD is due to chemical injury, a minimal interval of 1 year since the initial chemical injury is required.
  8. A Schirmer test result at 5 minute of ≥5 mm of wetting.
  9. Absence of active infectious keratitis in either eye at the Enrollment Visit.
  10. Have a life expectancy ≥ 2 years after enrollment.

You CAN'T join if...

  1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
  2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  3. Exposure keratopathy or lagophthalmos of the study eye.
  4. Persistent severe ocular surface inflammation and/or meibomian gland dysfunction
  5. Chemical injury occurred less than 12 months ago.
  6. Presence of ocular surface tumor.
  7. Uncontrolled diabetes with last hemoglobin A1C (HgA1C) >8.5.
  8. Presence of known allergies to any of the cLSC components.
  9. Current participation in another simultaneous medical investigation or trial.
  10. Unable to be compliant with or complete the requirements of the study.

Location

  • University of California accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

  • Sophie Deng (ucla)
    Sophie X. Deng, M.D., Ph.D., holds the Walton Li Chair in Cornea and Uveitis. She previously held the Joan and Jerome Snyder Chair in Cornea Diseases from 7/1/2019-6/30/2023.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT03957954
Phase
Phase 1 Limbal Stem-cell Deficiency Research Study
Study Type
Interventional
Participants
Expecting 20 study participants
Last Updated